Optimisation of a selection strategy for drug resistance osteosarcoma cell lines
Conference item
Low, K., Hills, F., Roberts, H. and Stordal, B. 2018. Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
Title | Optimisation of a selection strategy for drug resistance osteosarcoma cell lines |
---|---|
Authors | Low, K., Hills, F., Roberts, H. and Stordal, B. |
Abstract | Osteosarcoma is the most common primary malignant bone tumour and also the second highest cause of cancer related death in children and teenagers. The treatment of osteosarcoma including the use of neo-adjuvant chemotherapy in combination with surgery has increased the long-term survival rate of patients in last few decades. The most effective anticancer drug used against osteosarcoma are cisplatin, doxorubicin and high-dose methotrexate. The cure rate of osteosarcoma by surgery ranges from 15% to 20% and improves dramatically to 70% in the combination with chemotherapy. However, additional chemotherapy is palliative and toxic to approximately 40% of the patients with progression of osteosarcoma after front-line therapy. The aim of this study is to establish new drug-resistant osteosarcoma cell lines and investigate their mechanism of resistance. The human osteosarcoma cell lines MG-63 and HOS-143b will be treated with cisplatin, methotrexate and doxorubicin. The cell lines will expose to clinically relevant doses in the medium to select for the drug-resistant sublines. The morphological features of the drug-resistant subline will be observed using inverted microscopy. The growth rate of the developing drug-resistant sublines of MG-63 and HOS-143b will be calculated using an Image J method for determining cell confluence. The IC50s of each drug will be established in each cell line to optimise the doses used to treat the parental cell lines. The medium condition of MG-63 and HOS-143b is being optimised to mimic the clinical situation by removing antibiotic for both cell lines and bromodeoxyuridine (BrDU) for HOS143b.The growth rate of MG-63 and HOS-143b has been calculated and the doubling time is 34.15 ± 7.707 and 24.6 hours respectively. The Image J method for cell confluence has been optimised and shows a strong correlation to manual cell counts for each cell line. The correlation of Area Fraction and cell count for MG-63 is r=0.9823, which is significant with p value = 0.0005. For HOS-143b, the correlation is r=0.9823, which is also significant with p value = 0.0234. The expected outcome of this study is the establishment of drug-resistant sublines from MG-63 and HOS-143b. The drug-resistant sublines from MG-63 and HOS-143b will obtain a higher fold of resistant to their respective drugs in comparison with their parental cell lines and may also exhibit crossresistance to other drugs. These resistant sublines will be invaluable tools with which to study the resistance of anticancer drugs and to identify the methods to overcome resistance. |
Sustainable Development Goals | 3 Good health and well-being |
Middlesex University Theme | Health & Wellbeing |
Research Group | Biomarkers for Cancer group |
Conference | Research Degrees Students' Summer Conference |
Publication dates | |
04 Sep 2018 | |
Publication process dates | |
Deposited | 25 Jul 2022 |
Accepted | 04 Aug 2018 |
Output status | Published |
Language | English |
https://repository.mdx.ac.uk/item/89xyz
68
total views0
total downloads2
views this month0
downloads this month
Export as
Related outputs
Effect of post activation potentiation on weightlifting performance and endocrinological responses
Chavda, S., Sorensen, A., Vernau, J., Hills, F., Bishop, C. and Turner, A. 2025. Effect of post activation potentiation on weightlifting performance and endocrinological responses. Applied Sciences. 15 (2). https://doi.org/10.3390/app15020748Breast cancer risk and prevention in 2024: An overview from the Breast Cancer UK ‐ Breast Cancer Prevention Conference
Stordal, B., Harvie, M., Antoniou, M.N., Bellingham, M., Chan, D.S.M., Darbre, P., Karlsson, O., Kortenkamp, A., Magee, P., Mandriota, S., Silva, E., Turner, J.E., Vandenberg, L.N. and Evans, D.G. 2024. Breast cancer risk and prevention in 2024: An overview from the Breast Cancer UK ‐ Breast Cancer Prevention Conference. Cancer Medicine. 13 (18). https://doi.org/10.1002/cam4.70255The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: a systematic review and pre‐clinical study
Low, K., Foulkes, P., Hills, F., Roberts, H. and Stordal, B. 2024. The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: a systematic review and pre‐clinical study. Cancer Medicine. 13 (18). https://doi.org/10.1002/cam4.70248Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models
Stordal, B., Farrelly, A. and Hennessy, B. 2024. Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models. Molecular Biology Reports. 51 (1). https://doi.org/10.1007/s11033-024-09747-4Ovarian cancer: identifying and managing familial and genetic risk
Slade, E., Berg, L., Dworzynski, K., Manchanda, R., Barber, V., Bowen, R., Brentnall, A., Cameron, A., Davies, D., Davies, M., Evans, D., Hayward, J., McCluggage, W., Miles, T., Monahan, K., Moses, D., Robb, F., Rosenthal, A., Side, L., Stanford, J., Stordal, B. and Tripathi, V. 2024. Ovarian cancer: identifying and managing familial and genetic risk. National Institute for Health and Care Excellence.Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance
Slade, E., Berg, L., Dworzynski, K., Manchanda, R., Barber, V., Bowen, R., Brentnall, A., Cameron, A., Davies, D., Davies, M., Evans, D., Hayward, J., McCluggage, W., Miles, T., Monahan, K., Moses, D., Robb, F., Rosenthal, A., Side, L., Stanford, J., Stordal, B. and Tripathi, V. 2024. Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance. British Medical Journal. 385. https://doi.org/10.1136/bmj.q807Disaccharide compositional analysis of chondroitin sulphate using WAX HILIC-MS with pre-column procainamide labelling; application to the placenta in pre-eclampsia
Antia, I., Hills, F. and Shah, A. 2024. Disaccharide compositional analysis of chondroitin sulphate using WAX HILIC-MS with pre-column procainamide labelling; application to the placenta in pre-eclampsia. Analytical Methods. 16 (4), pp. 566-575. https://doi.org/10.1039/D3AY01578EIdentifying fibroblast growth factor receptor 3 as a mediator of periosteal osteochondral differentiation through the construction of microRNA-based interaction networks
Wells, L., Roberts, H., Luyten, F. and Roberts, S. 2023. Identifying fibroblast growth factor receptor 3 as a mediator of periosteal osteochondral differentiation through the construction of microRNA-based interaction networks. Biology. 12 (11). https://doi.org/10.3390/biology12111381Effect of hot water immersion on acute physiological responses following resistance exercise
Jackman, J., Bell, P., Van Someren, K., Gondek, M., Hills, F., Wilson, L. and Cockburn, E. 2023. Effect of hot water immersion on acute physiological responses following resistance exercise. Frontiers in Physiology. 14. https://doi.org/10.3389/fphys.2023.1213733A machine learning‑based image segmentation method to quantify in vitro osteoclast culture endpoints
Davies, B.K., Hibbert, A.P., Roberts, S.J., Roberts, H., Tickner, J.C., Holdsworth, G., Arnett, T.R. and Orriss, I.R. 2023. A machine learning‑based image segmentation method to quantify in vitro osteoclast culture endpoints. Calcified Tissue International and Musculoskeletal Research. 113 (4), p. 437–448.Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population
Radu, C., Matos de Melo Fernandes, N., Khalfe, S. and Stordal, B. 2023. Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population. Cancer Medicine. 12 (8), pp. 9879-9892. https://doi.org/10.1002/cam4.5670A survey into the use of priming techniques implemented by athletes and coaches to improve athletic performance
Collins, J., Bishop, C., Hills, F., Spiegelhalter, A., Cohen, R. and Turner, A. 2023. A survey into the use of priming techniques implemented by athletes and coaches to improve athletic performance. The Journal of Strength and Conditioning Research. 37 (1), pp. 107-113. https://doi.org/10.1519/jsc.0000000000004220Establishment and characterization of single and triple‐agent resistant osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2023. Establishment and characterization of single and triple‐agent resistant osteosarcoma cell lines. Advanced Biology. 7 (2). https://doi.org/10.1002/adbi.202200194Breastfeeding reduces the risk of breast cancer: a call for action in high-income countries with low rates of breastfeeding
Stordal, B. 2023. Breastfeeding reduces the risk of breast cancer: a call for action in high-income countries with low rates of breastfeeding. Cancer Medicine. 12 (4), pp. 4616-4625. https://doi.org/10.1002/cam4.5288Biomedical Science Exchanges at Middlesex University London
Stordal, B. 2019. Biomedical Science Exchanges at Middlesex University London. REALISE: Seminar on International Staff Mobility. Universities UK Boardroom, Woburn House, WC1H 9HQ, LondonBiomedical Science Exchanges
Stordal, B. 2018. Biomedical Science Exchanges. Middlesex University’s Erasmus Staff Training Week 2018. Middlesex University LondonBiomedical Science Exchanges
Stordal, B. 2018. Biomedical Science Exchanges. Middlesex University Staff Conference 2018: Learning through Change. Middlesex University London 27 Mar 2018A combination of cherry juice and cold water immersion does not enhance marathon recovery compared to either treatment in isolation: a randomized placebo-controlled trial
Difranco, I., Cockburn, E., Dimitriou, L., Paice, K., Sinclair, S., Faki, T., Hills, F., Gondek, M., Wood, A. and Wilson, L. 2022. A combination of cherry juice and cold water immersion does not enhance marathon recovery compared to either treatment in isolation: a randomized placebo-controlled trial. Frontiers in Sports and Active Living. 4. https://doi.org/10.3389/fspor.2022.957950Comparison of formative multiple choice questions using online platforms vs summative assessment: experience from an anatomy and physiology module
Stordal, B. 2015. Comparison of formative multiple choice questions using online platforms vs summative assessment: experience from an anatomy and physiology module. Middlesex University Annual Learning and Teaching Conference 2015: Revisiting Assessment. London, UK 13 Jul 2015Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy
Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. 2018. Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018ROR1-A novel biomarker for chemoresistance in ovarian cancer
Shafat, E., Hills, F. and Stordal, B. 2018. ROR1-A novel biomarker for chemoresistance in ovarian cancer. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018Mechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells
Bennacer, A., Roberts, H. and Stordal, B. 2018. Mechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics guidance [DG34]
Nixon, F., Albrow, R., Donna, B., Kroese, D., Adair, E., Bagshaw, J., Carrol, E., Driskell, O., Edwards, S., Fleming, S., Gray, J., Halligan, S., Hitchman, J., Hyde, C., McGinley, P., Messenger, M., Moseley, A., Naylor, P., Neely, D., Rahman Haley, S., Richards, S., Sculpher, M., Stevenson, M., Summerton, N., Wierzbicki, A., Bramley, M., Graham, J., Pepper, L., Ryyan, D., Stordal, B., Van Mann, U. and Wardley, A. 2018. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics guidance [DG34]. NICE.Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model
Stordal, B., Davey, M. and Davey, R. 2005. Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model. 96th AACR Annual Meeting. Anaheim California 16 - 20 Apr 2005 American Association for Cancer Research (AACR). pp. 348-349Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: linking changes in genotype to the resistant phenotype
Stordal, B., Peters, G., St. Heaps, L. and Davey, R. 2006. Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: linking changes in genotype to the resistant phenotype. 97th AACR Annual Meeting. Washington D.C., USA 01 - 05 Apr 2006 American Association for Cancer Research (AACR). pp. 133BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Stordal, B., Timms, K., Renuad, M., Thery, J., Farrelly, A., Williams, D., Potter, J., Tran, T., Korpanty, G., Cremona, M., Carey, M., Li, J., Li, Y., Aslan, O., O'Leary, J., Mills, G. and Hennessy, B. 2012. BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. 103rd Annual Meeting of the American Association for Cancer Research (AACR). Chicago 31 Mar - 04 Apr 2012 American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.AM2012-78A systematic approach to the study of cancer stem cells applied to ovarian cancer
Ffrench, B., Cooke, A., Stordal, B., O'Toole, S., Sheils, O., Gallagher, M. and O'Leary, J. 2012. A systematic approach to the study of cancer stem cells applied to ovarian cancer. 103rd Annual Meeting of the American Association for Cancer Research (ACCR). Chicago, USA 31 Mar - 04 Apr 2012 American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.AM2012-3382Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy
Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. 2018. Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy. 2018 NCRI Cancer Conference. Glasgow, Scotland 04 - 06 Nov 2018ROR1- A biomarker for chemoresistance in ovarian cancer
Syed, E., Hills, F. and Stordal, B. 2018. ROR1- A biomarker for chemoresistance in ovarian cancer. 2018 NCRI Cancer Conference. Glasgow, Scotland 04 - 06 Nov 2018Optimisation of a selection strategy for drug resistance osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2019. Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. 2019 NCRI Cancer Conference. Glasgow, UK 03 - 05 Nov 2019The EMTactivator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but predictive of survival
Rae, S., Keenan, J., Spillane, C., Blackshields, G., Madden, S. and Stordal, B. 2015. The EMTactivator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but predictive of survival. 2015 NCRI Cancer Conference. Liverpool, UK 01 - 03 Nov 2015BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data
Kalachand, R., Stordal, B., Madden, S., Chandler, B., Cunningham, J., Goode, E., Ruscito, I., Braicu, E., Sehouli, J., Ignatov, A., Yu, H., Katsaros, D., Lu, L., Mills, G., Broaddus, R., Lu, K., Carey, M., Timms, K., Rzepecka, I., Kupryjanczyk, J., Swisher, E., Harrell, M., Agnew, K., O'Riain, C., O'Toole, S., O'Leary, J., Thomas, D., Chaudhry, P., Srinivasan, R. and Hennessy, B. 2019. BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data. Lorne Cancer Conference. Lorne, Victoria, Australia 14 - 16 Feb 2019Comparative selection strategies for development of platinum-drug resistant ovarian cancer cell lines
Busschots, S., Kalachand, R., O'Toole, S., O'Leary, J., Hennessy, B. and Stordal, B. 2017. Comparative selection strategies for development of platinum-drug resistant ovarian cancer cell lines. 12th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. Sydney, Australia 10 - 14 Dec 2017PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC)
Kalachand, R., Cremona, M., Farrelly, A., Eustace, A., Stordal, B. and Hennessy, B. 2018. PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC). EACR25: The 25th Biennial Congress of the European Association for Cancer Research. Amsterdam, Netherlands 30 Jun - 03 Jul 2018The role of autophagy in canine osteosarcoma chemoresistance and metastasis
Kulatheepan, Y., Baines, S., Meeson, R. and Roberts, H. 2022. The role of autophagy in canine osteosarcoma chemoresistance and metastasis. 26th Annual Technological Advances in Science, Medicine and Engineering Conference 2022. Virtual 27 - 28 Aug 2022ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment
Pereira, J., Roberts, S. and Roberts, H. 2022. ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment. Research Students' Summer Conference. Middlesex University, Lonon, UK 22 - 23 Jun 2022Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis
Paternina Martinez, D., Roberts, S. and Roberts, H. 2022. Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis. Research Students' Summer Conference. Middlesex University, Lonon, UK 22 - 23 Jun 2022CRISPR/Cas9-mediated ATG7 knockout results in enhanced osteosarcoma chemosensitivity
Pears, A. and Roberts, H. 2022. CRISPR/Cas9-mediated ATG7 knockout results in enhanced osteosarcoma chemosensitivity. Bone Research Society Annual Conference. Manchester Metropolitan University, Manchester, UK 06 - 08 Jul 2022ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment
Pereira, J., Roberts, S. and Roberts, H. 2022. ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment. Bone Research Society Annual Conference. Manchester Metropolitan University, Manchester, UK 06 - 08 Jul 2022Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis
Paternina Martinez, D., Roberts, S. and Roberts, H. 2022. Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis. Bone Research Society Annual Conference. Manchester Metropolitan University, Manchester, UK 06 - 08 Jul 2022Intentionality for inclusivity - the journey at Middlesex University
Roberts, H., Punev, I., Allardyce, D., Kyprianou, A., Appiah, S., Megeney, A., Calin, A., Gallacher, D. and Mill, R. 2022. Intentionality for inclusivity - the journey at Middlesex University. McGraw Hill.Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer [Review - Intervention]
Patel, A., Kalachand, R., Busschots, S., Doherty, B., Kapros, E., Lawlor, D., Hall, N. and Stordal, B. 2022. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer [Review - Intervention]. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD008766.pub3The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival
Rae, S., Spillane, C., Blackshields, G., Madden, S., Keenan, J. and Stordal, B. 2022. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival. Human Cell. 35 (5), pp. 1547-1559. https://doi.org/10.1007/s13577-022-00744-y